DarioHealth Corp (DRIO)
NASDAQ:DRIO
Want to see DRIO full AI Analyst Report?
DRIO Stock Chart & Stats
$11.72
-$0.63(-41.18%)
At close: 4:00 PM EST
$11.72
-$0.63(-41.18%)
Day’s Range― - ―
52-Week Range$5.94 - $17.74
Previous CloseN/A
Volume780.96K
Average Volume (3M)33.32K
Market Cap
$51.63M
Enterprise Value$68.22M
Total Cash (Recent Filing)$20.26M
Total Debt (Recent Filing)$31.82M
Price to Earnings (P/E)5.6
Beta0.52
Next Earnings
Aug 17, 2026EPS Estimate
-1.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.25
Shares Outstanding7,312,398
10 Day Avg. Volume41,359
30 Day Avg. Volume33,324
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)8.32
Price to Sales (P/S)25.26
P/FCF Ratio-21.65
Enterprise Value/Market Cap1.32
Enterprise Value/Revenue3.22
Enterprise Value/Gross Profit5.69
Enterprise Value/Ebitda-1.95
Forecast
1Y Price Target
$10.50Price Target Upside-10.41% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-4.79
Revenue Forecast (FY)$26.16M
Bulls Say, Bears Say
Bulls Say
High-margin Unit EconomicsSustained, high B2B2C gross margins (~80%) and a 57% overall gross margin signal durable unit economics. As partner-led, recurring-subscription revenue scales, strong margins can drive operating leverage and improve cash conversion, supporting long-term profitability if growth materializes.
Large Channel Distribution ReachAccess to >175M covered lives via channel partners creates a structurally large addressable market and efficient distribution, lowering customer-acquisition friction. This partner-led scale can produce step-change revenue growth and recurring enrollments as integrations convert, supporting durable expansion.
Proprietary Data & Clinical EvidenceA large proprietary data repository and extensive peer‑reviewed evidence underpin personalized AI engagement and clinical credibility. This creates a competitive moat for outcomes-driven contracts, enabling differentiated retention and positioning for value- or claims-based revenue over the medium term.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow indicates ongoing cash burn and dependence on external financing. This constrains the company’s ability to invest in sales, implementation and product development, and raises risk if partner conversions or financings are delayed.
Continued Operating LossesDespite margin gains, the company remains operationally loss-making. Persistent GAAP and non‑GAAP operating losses imply the business has not yet reached operating leverage; without faster revenue scale these losses will continue to pressure liquidity and strategic optionality.
Choppy Revenue Trend & Conversion Timing RiskA declining TTM revenue trend and historically choppy growth reduce visibility into sustainable topline momentum. Much of future growth depends on converting large 2025-signed and partner-led deals; timing and onboarding uncertainty makes revenue realization and cash flow unpredictable.
DarioHealth News
DRIO FAQ
What was DarioHealth Corp’s price range in the past 12 months?
DarioHealth Corp lowest stock price was $5.93 and its highest was $17.74 in the past 12 months.
What is DarioHealth Corp’s market cap?
DarioHealth Corp’s market cap is $51.63M.
When is DarioHealth Corp’s upcoming earnings report date?
DarioHealth Corp’s upcoming earnings report date is Aug 17, 2026 which is in 64 days.
How were DarioHealth Corp’s earnings last quarter?
DarioHealth Corp released its earnings results on May 13, 2026. The company reported -$1.25 earnings per share for the quarter, beating the consensus estimate of -$1.48 by $0.23.
Is DarioHealth Corp overvalued?
According to Wall Street analysts DarioHealth Corp’s price is currently Overvalued.
Does DarioHealth Corp pay dividends?
DarioHealth Corp does not currently pay dividends.
What is DarioHealth Corp’s EPS estimate?
DarioHealth Corp’s EPS estimate is -1.22.
How many shares outstanding does DarioHealth Corp have?
DarioHealth Corp has 7,312,398 shares outstanding.
What happened to DarioHealth Corp’s price movement after its last earnings report?
DarioHealth Corp reported an EPS of -$1.25 in its last earnings report, beating expectations of -$1.48. Following the earnings report the stock price went down -6.682%.
Which hedge fund is a major shareholder of DarioHealth Corp?
Currently, no hedge funds are holding shares in DRIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DarioHealth Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-23.65%
12-Months-Change
Fundamentals
Return on Equity
93.18%
Trailing 12-Months
Asset Growth
-10.66%
Trailing 12-Months
Company Description
DarioHealth Corp
DarioHealth Corp. is a digital therapeutics enterprise operating across the United States, Canada, the European Union, Australia, and New Zealand. The company delivers a suite of digital health solutions, including its 'Dario' metabolic programs designed to address conditions like diabetes, hypertension, and weight management. They also offer 'Dario Musculoskeletal' for preventing and treating common MSK conditions, and 'Dario' behavioral health solutions to improve access to evidence-based care. Their offerings extend to general chronic condition management solutions and DarioEngage, a proprietary care management platform. In terms of hardware, DarioHealth provides smart glucose meters, Bluetooth-connected blood pressure cuffs, digital scales, biofeedback sensor devices, and disposables such as test strip cartridges and lancets for blood glucose monitoring systems. Furthermore, they offer comprehensive diabetes management programs that integrate lifestyle changes, healthy eating guidance, advanced tracking tools, and live coaching. Founded in 2011, the company was formerly known as LabStyle Innovations Corp. before officially changing its name to DarioHealth Corp. in July 2016. Its headquarters are located in New York, New York.
DRIO Company Deck
DRIO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized sequential revenue growth, a materially improved cost structure, a sizeable commercial pipeline ($127M) and expanding channel distribution (targeting >175M covered lives), supported by proprietary data assets and early AI-driven engagement gains. Key positives include meaningful OpEx reductions, improving margins on core B2B2C offerings (~80% non-GAAP gross margin), a clear strategic push to participate in care- and outcomes-based revenue via partnerships, and accelerating consumer product demand. Offsetting these positives are a year-over-year revenue decline tied to deliberate removal of non-recurring pharmaceutical revenue, continued GAAP and non-GAAP operating losses, dependence on the timing of large partner conversions (implementation and onboarding risks), limited near-term revenue visibility and an ongoing strategic review that introduces some uncertainty. On balance, management presented measurable operational improvements and a clear path toward scaled, higher-margin channel revenue, while acknowledging conversion and timing risks that remain to be resolved.View all DRIO earnings summariesDRIO Stock 12 Month Forecast
Average Price Target
$10.50
▼(-10.41% Downside)
Technical Analysis
Ownership Overview
7.32% Insiders
1.59% Mutual Funds
8.36% Other Institutional Investors
81.82% Public Companies and
Individual Investors